When gastrointestinal stromal tumour (GIST), the most common form of sarcoma, was first
recognized as a distinct pathological entity in the 1990s, patients with advanced-stage …

Gastrointestinal stromal tumours (GISTs) are a paradigm for the development of
personalized treatment for cancer patients. The nearly simultaneous discovery of a …

Background Targeting of KIT and PDGFRA with imatinib revolutionised treatment in
gastrointestinal stromal tumour; however, PDGFRA Asp842Val (D842V)-mutated …

Gastric cancer is a heterogeneous cancer, making treatment responses difficult to predict.
Here we show that we identify two distinct molecular subtypes, mesenchymal phenotype …

Background Until now, only imatinib and sunitinib have proven clinical benefit in patients
with gastrointestinal stromal tumours (GIST), but almost all metastatic GIST eventually …

Background No effective therapeutic options for patients with unresectable imatinib-resistant
gastrointestinal stromal tumour are available. We did a randomised, double-blind, placebo …

Background Gastrointestinal stromal tumour is the most common sarcoma of the intestinal
tract. Imatinib mesylate is a small molecule that inhibits activation of the KIT and platelet …

BACKGROUND Recent breakthroughs regarding gastrointestinal stromal tumors (GIST) and
their pathogenesis have redefined diagnostic criteria and have led to the development of …

Purpose To assess potential differences in progression-free or overall survival when
imatinib mesylate is administered to patients with incurable gastrointestinal stromal tumors …

Gastrointestinal stromal tumors (GIST) are the most common type of soft tissue sarcoma that
occur throughout the gastrointestinal tract. Most of these tumors are caused by oncogenic …